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SCIENTIFIC SUMMARY 
 
INTRODUCTION 
Renal ischemia/reperfusion (I/R)-induced acute renal failure still has high rates of morbidity and 
mortality. In renal transplantation, I/R has a major role in delayed graft function and chronic allograft 
injury. The exact pathomechanism of I/R is still unclear, but growing evidence indicates that sex 
differences exist in kidney response to renal ischemic injury (1-3).  
Our previous studies have revealed the importance of a nitric oxide (NO) pathway showing the 
pivotal role of NO and endothelin in the gender-dependent renal response to ischemic injury and 
aging (4). Moreover, we also demonstrated the importance of Na+/K+ATPase-a1 and heat shock 
protein (HSP)72 in this gender dependent injury (1-3).  
Erythropoietin (EPO) is an essential growth factor of hemopoietic progenitor cells (5), but its extra-
hemopoietic effects imply additional therapeutic possibilities. Indeed, a wealth of experimental data 
is being generated with respect to the protective effect of EPO against the ischemic myocardium 
(6,7) liver (8,9) and renal injury (10-12). Moreover, several clinical trials also are being processed. 
According to the trial of the Hannover Medical School (Germany), rHuEPO alpha significantly 
increased the glomerular filtration rate in transplant patients (ClinicalTrials.gov number: 
NCT00425698).  
The anti-apoptotic, anti-oxidative, and anti-inflammatory effects of EPO have been investigated in 
several studies (12-16), but the complete molecular mechanisms involved in the prevention of renal 
I/R injury are not yet fully understood.  
A growing body of evidence supports the connection between EPO and the HSP70 family. It has been 
shown that EPO attenuates myocardial infarct size by enhancing the HSP70 protein level (17). In 
addition, the induction of HSP70 by EPO administration inhibits apoptotic cell death in rat ischemic 
kidney (18). 
Furthermore, EPO exerts its immediate anti-apoptotic effects via an activation of multiple signalling 
pathways of which phosphorylation and activation of the phosphatidylinositol 3-kinase (PI3-kinase) 
(19) seems to play a pivotal role. SGK1 is an anti-apoptotic down-stream kinase of the PI3-kinase 
pathway. The expression and activation of the serum and glucocorticoid-regulated kinase 1 (SGK1) is 
increased by various cell stress stimuli such as hyperosmotic stress, ultraviolet radiation, heat shock 
(21), oxidative stress (22) and hypoxia (23). In a previous study, we could show that SGK1 is markedly 
induced after I/R in the kidney and upregulation of SGK1 directly protects kidney tubulus cells from 
hypoxia (26). Gender-specific aspects were not investigated. 
Furthermore, we demonstrated that renal I/R injury induces a gender-dependent HSP72 expression 
(3), which maintains basolateral membrane localization of an essential tubular sodium transporter - 
the Na+/K+ATPase. Under ischemic conditions, its enzyme activity decreases in a gender- and time-
dependent manner and because of the disruption of the actin cytoskeleton, Na+/K+ATPase-a1 
internalizes or translocates from the basolateral to the apical membrane of renal tubular cells.  
Under stress conditions, the heat shock factor 1 (HSF-1) is the major transcription factor that is 
responsible for induction of HSPs (24). Furthermore, hypoxia inducible factor-1 is another 
transcription factor that gained more attention in ischemic models since it triggers the expression of 
several factors which play a central role in the defense mechanisms against ischemia (25).  
There is not much known about gender specific differences of HSF-1 and HIF-1 pathways, and 
although the PI3-kinase pathway has long been known to be regulated by estrogen, sex differences in 
SGK1 was not investigated under in vivo stress conditions either.  
 
AIMS 
Regarding the proven beneficial effects of EPO in renal ischemic injury and our results showing major 
effects of HSP72 and SGK-1 during renal I/R injury, the aims of our project was to investigate:  
1. whether EPO treatment is protective against serious, unilateral renal I/R damage;  
2. whether there is a difference in EPO effects between female and male rats;  
3. the role of SGK-1, HSP72 and Na+/K+ATPase in EPO effects;  
4. whether there are gender specific differences in SGK-1 expression after I/R in the kidney; 
5. the two transcriptional factor pathways (HSF-1 and HIF-1) in serious, unilateral renal I/R damage;  
6. possible gender differences in these two signaling pathways. 
 
 
 
 
RESULTS 
 
1. EPO treatment and SGK1 in renal ischemia/reperfusion (I/R) injury 
In line with earlier observations of other experimental studies, we could also show that 
erythropoietin (EPO) has markedly protected the kidney from ischemic injury as reflected by 
decreased post-ischemic serum creatinine and blood urea nitrogen levels. This was partly mediated 
by upregulation of SGK1.  
In vitro, cultures of kidney cells were exposed to hypoxia. Incubation with EPO at a dosis of 400 U/ml 
exerted a marked protective effect on cell death. This was paralleled by up-regulation of SGK1 
expression as well as phosphorylation, thus activation. Moreover, down-regulation of SGK1 
expression through small interfering RNA technique ameliorated the anti-apoptotic effect of EPO 
treatment suggesting that upregulation of SGK1 is not an epiphenomenon, but rather a significant 
contributor to the protective EPO effects in this model. 
In the in vivo rat model of unilateral renal I/R injury, rats were treated with 500 U/kg EPO 24 h prior 
to ischemia. EPO resulted in less severe tissue injury and ameliorated the elevation in creatinine and 
urea nitrogen levels 24 h after reperfusion. Furthermore, SGK1 expression and phosphorylation were 
higher in EPO compared to vehicle treated rats suggesting that SGK1 might be involved also in the in 
vivo effects of EPO (Figure 1A-B.). 
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Figure 1A. Erythropoietin (EPO) induced SGK1 mRNA and protein expression. (A) SGK1 mRNA 
expression was assessed by real-time PCR analysis. I/R caused elevated SGK1 mRNA expression 2 h 
after reperfusion (%P<0.05 vs. shams). EPO induced SGK1 mRNA expression in all animal groups 
(*P<0.01 vs. vehicle treated animals). 24 h after reperfusion, SGK1 mRNA expression was decreased 
compared to the 2 h-animals in the EPO treated animals (+P<0.01 vs. I/R 2h+EPO). (B) SGK1 protein 
expression was assessed by Western blot analysis. I/R caused elevated SGK1 protein expression 24 h 
after reperfusion (%P<0.05 vs. Shams). 
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Figure 1B. Immunofluorescent staining of the kidneys showed marked SGK1 expression located in the 
tubuli. Up-regulated total SGK1 (green fluorescence) (left panel) and phosphorylated-SGK1 (SGK1-P, 
red fluorescence) were stained in EPO treated animals in the sham-operated group and 2h after 
ischemia in the tubular cells. 24 h after reperfusion, no marked difference was demonstrated 
between the vehicle and EPO treated animals. Cell nuclei were labeled with Hoechst (blue staining). 
 
 
2. Gender differences in the expression pattern of SGK1 in renal I/R injury 
We could show that there is a marked sex-specific expression pattern of SGK1 expression. In male 
animals, there was higher expression and higher activation of SGK1 after I/R when compared to 
female rats (Figure 2.). This higher expression was demonstrated both at the level of mRNA and 
protein, moreover using immunofluorescent staining localization of total and phosphorylated SGK1 
was determined.  
In order to determine which sex hormone could be involved in the regulation of SGK1, cells were 
treated with different concentrations of either testosterone or estrogen, whereas in vivo, animals 
were gonadectomized. 
In vitro, treatment of kidney cells with testosterone stimulated, whereas in vivo castration of males 
decreased SGK1 expression suggesting that SGK1 might be regulated by testosterone.  
 
 
 
Figure 2. Protein expression of SGK-1 after renal I/R measured by Western blot analysis. I/R caused 
elevated SGK-1 protein expression 2 h after reperfusion in males compared to control males 
(%P<0.001 vs. control male). SGK-1 protein abundance was higher both 2 h and 24 h after ischemia in 
males when compared to females (*P<0.05 vs. female, respectively). Castration of males decreased 
SGK-1 level compared to males at all examined time-points (#P<0.01 vs. male, respectively). 
 
 
3. EPO treatment and HSP72 and  NA
+
/K
+
ATPase in renal I/R injury 
Survival. The EPO administration resulted in a remarkable amelioration of male’s postischemic 
survival. Although all untreated males died as a result of ARF by the third day, those treated with EPO 
survived until the sixth day, almost twice as long as those untreated. EPO resulted in a slight 
improvement in females as well. To note, however, irrespective of the EPO administration, pared 
with their male counterparts (Figure 3.).  
 
Figure 3. Effect of EPO treatment on the postischemic survival (A); in male + vehicle (-) and male + 
EPO (,) (B); in female + vehicle (:) and female + EPO (⌂) (C) (n = 8). The cumulative proportion 
surviving analysis of significance was performed by Kaplan–Mayer analysis (log-rank test). *P # .05 
versus male + vehicle. 
 
 
Serum EPO level. The serum level of endogenous EPO was higher in males versus females not only in 
controls but also in both postischemic time points. EPO administration increased control and T2 EPO 
* 
# 
# # 
% 
levels in both genders, whereas at T24, the effect of exogenous EPO treatment disappeared. The 
dynamics of postischemic changes in serum EPO levels followed a remarkably different manner 
between males and females; in males, the already higher EPO decreased only at T24, whereas in 
females, the EPO level dropped to a third of the control value already at T2 (Table I.).  
 
Serum EPO (mIU/mL) control T2 T24 
Female+vehicle 7.7 ± 4.1 2.5 ± 0.8 * 0.3 ± 0.6 *# 
Male+vehicle 11.9 ± 4.2 § 10.0 ± 2.4 § 1.4 ± 1.7 § *# 
Female+EPO 15.2 ± 4.7 & 7.3 ± 3.1 &* 1.4 ± 0.6 &*# 
Male+EPO 24.7 ± 15.0 & 25.7 ± 6.6 §& 1.17 ± 0.3 *# 
Table I. Serum levels of endogenous and exogenous EPO after renal ischemia-reperfusion injury in 
female and male rats (n = 8/group) Values are means ± SD. yP < .05 versus female. zP < .05 versus 
vehicle-treated. xP < .05 versus control. {P < .05 versus T2. 
 
HSP72 protein levels. The HSP72 level was higher in untreated females than in males at every time 
point. After the ischemic insult, the HSP72 protein levels increased in a gender-dependent manner. In 
females, HSP72 reached its maximum at T2, whereas in males, the rate of increase was slower both 
with and without EPO treatment. EPO increased the HSP72 protein level in males at T24, whereas in 
females, the already higher HSP72 level was not elevated. 
Na+/K+ATPase-a1 subunit protein levels. Similar to HSP72, the postischemic changes in Na+/K+ 
ATPase-a1 protein levels were different between the sexes. Na+/K+ATPase-a1 protein levels were 
higher in untreated females than in males at every time point (Figure 4). EPO treatment was effective 
only in males by increasing the protein level at T24 to a level even higher than the EPO-treated 
females. 
 
 
Figure 4. Effect of renal I/R injury on protein expression of HSP72 (Panel A) and Na+/K+ATPase- a1 in 
female + vehicle, female + EPO, male + vehicle, and male + EPO rat kidney. Protein expression was 
determined in kidney samples from control and at T2 and T24 of reperfusion after 50 minutes of 
renal ischemia (n = 8/group). Top: representative examples of Western blot analysis of HSP72 and 
beta-actin in kidney. Female + vehicle (gray); female + EPO (striped gray); male + vehicle (black); male 
+ EPO (striped black). Values are mean ± SD. xP < .05 versus female, &P < .05 versus vehicletreated, 
*P < .05 versus T0, #P < .05 versus T2.  
 
Immunolocalization of HSP72 and Na+/K+ATPase- a1 subunit. Immunofluorescent staining was used 
to investigate the potential relationship between HSP72 and Na+/K+ATPase-a1. In the tubules of 
control rats, Na+/K+ATPase-a1 was localized on the basolateral membrane domain of tubular cells, 
with minimal staining in the cytosol or the apical domain. No gender differences were observed at 
this time point. In contrast, HSP72 staining was virtually undetectable in the tubular cells of control 
rats. After ischemic injury, Na+/K+ATPase-a1 became more prominent in the cytosol compared with 
the controls, but this internalization was less pronounced in untreated females versus males. After 
EPO treatment, however the Na+/K+ATPase-a1 localization remained more pronounced on the 
basolateral membrane in males as well. 
 
 
4. EPO treatment and HIF1α / HSF1 in renal I/R injury 
Immunolocalization of HIF1α. Immunofluorescent staining was used to describe the source of the 
HIF1α in renal cortex (Figure 5.). In the peritubular fibroblasts of T2 rats, HIF1α became stabile and 
transported toward the nucleus giving the opportunity to bind to hypoxia responsible element 
resulting increased EPO expression. 
 
Figure 5. Localization of HIF 1a (green) in the peritubular fibroblasts of representative samples using 
immunofluorescent staining followed by confocal images. 
 
HIF1a protein levels. The HIF1α level was higher in untreated males than in females at every time 
point (Figure 6.). After the ischemic insult, the HIF1α protein levels increased in a gender-dependent 
manner. In females, HIF1α increased by T2 and even further by T24. In males, the rate of the increase 
was more robust in untreated rats compared to females, whereas in those receiving EPO this raise 
completely diminished.  
HSF1 protein levels. The postischemic changes in HSF1 protein levels were different between the 
sexes. HSF1 was higher in untreated females than in males at every time point (Figure 6.). However, 
EPO treatment lowered the HSF1 in both postischemic female groups to a level comparable to that of 
controls. 
 
 
Figure 6. Effect of renal I/R injury on protein expression of HIF 1 α and HSF1 in female + vehicle, 
female + EPO, male + vehicle, and male + EPO rat kidney. Protein expression was determined in 
kidney samples from control and at T2 and T24 of reperfusion after 50 minutes of renal ischemia (n = 
8/group). Female + vehicle (white); female + EPO (light gray); male + vehicle (black); male + EPO (dark 
gray). Values are mean ± SD. x P < .05 versus female, &P < .05 versus vehicle treated, *P < .05 versus 
T0, #P < .05 versus T2.  
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CONCLUSIONS 
Our results based on both survival and molecular studies suggest that EPO protects against severe, 
unilateral renal I/R injury, especially in male rats. Furthermore, we believe this beneficial effect might 
be partly the result of EPO’s HSP72-mediated impact on Na+/K+ATPase-α1. 
Moreover, our data report a new signaling molecule to be involved in EPO cytoprotective actions, 
since the present study identified for the first time an important role of SGK1 in the anti-apoptotic 
and possibly, renoprotective effect of EPO during renal I/R injury.  
The EPO induced up-regulation of SGK1 was observed both under in vitro and in vivo circumstances. 
Moreover, in vitro, inhibition of SGK1 blocked the protective effect of EPO under hypoxia confirming 
a direct role of SGK1 in the EPO effect. 
These observations provide insights into a novel signaling mechanism by which EPO partly exerts its 
potent tissue protective actions. Given our results along with previous reports, the clinical use of EPO 
possibly leading to reduced cellular damage due to ischemic events should be considered, however, 
further investigations are needed to establish the feasibility and efficacy of EPO in clinical settings. 
 
Our study has revealed a gender-dependent protective mechanism during renal I/R injury. In males 
mostly the HIF 1α, while in females the HSF is the dominant transcriptional pathway. The EPO 
treatment results in disappearance of the characteristic signal pathway activation in both genders. 
The explanation for that could be either a direct negative feedback effect on the transcription factors 
or an indirect renal protective effect of EPO by which these transcriptional factors do not need to be 
activated.  
We could also demonstrate that the anti-apoptotic SGK1 shows a gender-specific expression pattern 
after renal I/R with higher levels in male rats. These results confirm previous contradictory reports 
showing that SGK1 might be up-regulated and activated by testosterone. 
 
 
OUTLOOK 
With respect to the future, the effective and safe administration of EPO and EPO mimetic drugs may 
also have therapeutic potential in preventing ischemic kidney injury in clinical settings such as open-
heart, aorta surgery and renal transplantations. Finally, the individualized EPO administration 
between males and females might also be considered in every-day clinical practice. 
 
OTHER RESULTS: 
 
Since we found that HSP72 and steroids play a key role in ischemic renal injury we focused on 
another field too.  Smoking is the leading risk factor of chronic obstructive pulmonary disease (COPD) 
and lung cancer. Corticosteroids are abundantly used in these patients; however, the interaction of 
smoking and steroid treatment is not fully understood. Heat shock proteins (Hsps) play a central role 
in the maintenance of cell integrity, apoptosis and cellular steroid action. To better understand 
cigarette smoke-steroid interaction, we examined the effect of cigarette smoke extract (CSE) and/or 
dexamethasone (DEX) on changes of intracellular heat shock protein-72 (Hsp72) in lung cells. 
Alveolar epithelial cells (A549) were exposed to increasing doses (0; 0.1; 1; and 10 μM/μl) of DEX in 
the medium in the absence(C) and presence of CSE. Apoptosis, necrosis, Hsp72 messenger-
ribonucleic acid (mRNA) and protein expression of cells were measured, and the role of Hsp72 on 
steroid effect examined.  
 
 
 
Cell number after the treatments: Under control conditions cells proliferated, reaching about 
8.55±1.1×105 final cell number/vial. Following DEX treatment no significant change in cell number 
was noted. In contrast, CSE treatment significantly reduced the cell number 24 h after incubation as 
compared to controls. CSE+DEX co-treatment dose-dependently and significantly increased the total 
cell count as compared to CSE treatment alone, reaching similar number in both DEX (10) groups 
(C+DEX (10): 10.22±0.77×105 cell/vial; CSE+DEX (10): 8.86±0.49×105 cell/vial). 
Apoptosis: DEX slightly decreased the number of the apoptotic cells in controls, reaching statistical 
significance only in the C+DEX (10) group. In steroid-naïve CSE-treated cells, apoptosis tripled as 
compared with the steroid naïve controls. DEX treatment significantly reduced apoptosis in all CSE-
treated groups, abolishing the difference between CSE-treated and respective control groups.  
Necrosis: The ratio of necrotic cells did not differ in controls, whether DEX treatment was used or not 
(C, 3.2±0.63%; C+DEX (0.1), 2.95±0.36%; C+DEX (1), 3.2±1.39%; C+DEX (10), 3.08±1.32%). In contrast, 
CSE significantly increased the number of necrotic cells. Similarly to controls, DEX had no additional 
effect on necrosis in CSE-treated cells resulting in significantly higher necrotic cell rate in all CSE 
groups (CSE, 6.24±1.02%; CSE+DEX (0.1), 6.12±2.11%; CSE+DEX (1), 6.68±1.1%; CSE+DEX (10), 
4.7±0.75%; p<0.05 vs. respective control group). 
 
 
 
 
 
 
 
 
In conclusion, our data confirmed that CSE induces apoptosis and necrosis in alveolar epithelial cells. 
DEX reduces CSE-induced cellular damage, by decreasing apoptosis. This is the first evidence of DEX-
CSE interaction showing a key role of Hsp72 in alveolar epithelial cell survival. Our siRNA experiments 
confirmed that elevated Hsp72 is essential in the observed anti-apoptotic and protective effects of 
DEX following CSE exposure. Hsp72 might represent a new key molecule and a potential therapeutic 
target in smoke exposed lung cells. As millions of smokers are treated with glucocorticoids new data 
on cigarette smoke and glucocorticoid interaction are needed. Future experiments are necessary to 
evaluate the role of Hsp72 in smoker and non-smoker COPD patients, especially assessing the effects 
on alveolar destruction. 
 
 
CLINICAL STUDIES: 
 
Beside our basic science works we also examined some clinical problem. One of them is the role of 
HSP72 genetic polymorphism in renal transplant children. Our findings suggest an association 
between the carrier status of HSPA1B (1267)G with urinary tract malformations, leading to end-stage 
renal disease requiring kidney transplantation. This observation raises further questions about the 
clinical and therapeutic relevance of this polymorphism to pediatric nephrology. 
 
Arterial stiffness (Ast) individually predicts cardiovascular (CV) mortality. Ast increases via vascular 
calcification and can be characterized by pulse wave velocity (PWV). We assessed the influence of 
mineral and bone metabolism on Ast in dialyzed (D) and renal transplanted (Tx) children by 
measuring fetuin-A and bone markers [bone-specific alkaline phosphatase (BALP); beta-CrossLaps 
(β)]. Normalized PWV/height (PWV/h) of 11 D and 17 Tx patients was measured by applanation 
tonometry. Levels of calcium (Ca), phosphate (P), fetuin-A, and bone markers were analyzed. Ca × 
P/fetuin-A ratio was calculated to characterize the balance of calcification and inhibition. Cumulative 
dose of calcitriol was also assessed. Fetuin-A was lower in D and Tx compared with healthy controls. 
Bone markers and Ca × P/fetuin-A of D were significantly higher than those of Tx and controls. In D 
PWV/h correlated with Ca × P/fetuin-A and BALP (r=0.8; p=0.005, r=0.6, p=0.05, respectively); BALP 
correlated with Ca × P/fetuin-A (r=0.7, p=0.01). In Tx, there was a correlation between calcitriol 
administered before transplantation and PWV/h (r=0.5, p=0.04). Increased bone turnover was 
coupled with an increased potential of calcium-phosphate precipitation, as shown by the increased 
Ca × P/fetuin-A. It might explain the connection between disturbed mineral and bone metabolism 
and Ast. Tx might be beneficial on Ast, though follow-up studies are needed. 
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